CELLULAR ACTIVATION IN PPH--ENDOGENOUS AND EXOGENOUS PROSTACYCLIN

PPH 中的细胞激活——内源性和外源性前列环素

• 批准号: 6115646
• 负责人: BRIAN W CHRISTMAN
• 金额: $ 3.64万
• 依托单位: VANDERBILT UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6115646
• 关键词: clinical research; drug administration rate /duration; drug screening /evaluation; human subject; human therapy evaluation; platelet activation; platelet aggregation inhibitors; prostacyclins; prostaglandin F; pulmonary hypertension

This study is to determine the physiological and biochemical mechanisms of tachyphlaxis to infused Flolan in patients with Primary Pulmonalry Hypertension by examining the relationship between the rate of infusion of Flolan and a measurable plasma metabolite, 6-keto-PGF1a, during the initial dosing as well as during chronic administration. This study will also investigate the changes associated with the "cessation Syndrome" that occurs when infusion is abruptly interrupted and evaluate the effect acute and chronic Flolan infusion on in vivo platelet activation. We are currently calculating data from some of our normal volunteers and continue to enroll PPH patients.

本研究旨在确定生理和生化机制 输注 Flolan 对原发性肺病患者的快速止痛效果 通过检查输注速度与高血压的关系 Flolan 和可测量的血浆代谢物 6-酮-PGF1a 初始给药以及长期给药期间。这项研究将 还调查与“戒烟综合症”相关的变化 突然中断输注时发生的情况并评估效果 急性和慢性Flolan输注对体内血小板活化的影响。 我们目前正在计算一些正常志愿者的数据 继续招募 PPH 患者。